Fecal microbial transplantation: a novel approach to eradicate antibiotic-resistant gut bacteria
The discovery of antibiotics in the early 20th century had an enormous impact on modern medicine, dramatically reducing mortality associated with infections. However, the emergence of drug – resistant pathogens has occurred due to greater availability and inappropriate use of antibiotics in healthcare and agriculture and has become a global health concern. In particular, multi-drug resistant organisms such as vancomycin-resistant Enterococci (VRE), methicillin resistant Staphylococcus aureus (MRSA) and extended spectrum beta-lactamase (ESBL) and Clostridium difficile (C. difficile). All of the bacteria that live inside the human gastrointestinal tract are referred to as the microbiota. The microbiota of the human gut is a complex ecosystem with the potential to be an enormous reservoir of antibiotic resistance (ABR) genes, known as the ‘gut resistome.’ Antibiotic resistance may arise in a number of different ways, including the accumulation of point mutations and horizontal gene transfer from other bacterial populations to potentially pathogenic bacteria. The increase in the prevalence and incidence of antibiotic resistant bacteria now presents a severe challenge in the treatment of patients infected with these multidrug-resistant organisms.
A major complication associated with antibiotic use is C. difficile infection (CDI). C. difficile is an anaerobic, spore-forming, toxin-producing bacteria that is present in 3% of the healthy adult population; however, up to 20-50% of adults in hospitals and long-term care facilities become colonized. C. difficile infection is treated with the antibiotics metronidazole or vancomycin, but the risk of the recurrence is 20-30% within 30 days of initial treatment and increases further up to 50% after a second episode. Fecal microbiota transplantation (FMT) is the infusion of lightly processed stool from healthy donors into the gastrointestinal tract of a recipient. FMT has emerged as an efficient and safe therapy for recurrent C. difficile infection (RCDI), with over a 90% success rate.
In our single-center study, patients with RCDI (n=20) received FMT from universal donors via colonoscopy. Stool samples were collected from donors (n=3) and patients prior to and following FMT. Bacterial DNA was extracted from patient and donor stool samples and sequenced using shotgun metagenomics. Using the sequencing data, taxonomic classification of the microbiota was performed using a database from the National Center for Biotechnology Information (NCBI). Another healthy cohort (n=87) from the Human Microbiome Project (HMP) were included with our patient and donor samples in the resistome analysis using the Comprehensive Antibiotic Resistance Database (CARD). The purpose of this was to ensure that our three healthy donors’ resistome was representative of a healthy population. Metagenomic results were corroborated through a DNA microarray containing 354 different ABR genes.
RCDI patients had a greater number and diversity of ABR genes compared with donors and healthy controls. Beta-lactam, multidrug efflux pumps, fluoroquinolone, and antibiotic inactivation ABR genes were increased in the microbiota of RCDI patients while the donors’ microbiota primarily had tetracycline resistance genes. RCDI patients were dominated by Proteobacteria with Escherichia coli and Klebsiella most prevalent. FMT resulted in a resolution of symptoms which correlated directly with a decreased number and diversity of ABR genes and increased Bacteroidetes and Firmicutes with reduced Proteobacteria. ABR gene profiles were maintained in recipients for up to a year following FMT. Results from the DNA microarray were consistent with the results from the metagenomic analysis. In our study, we demonstrated that FMT was effective in the treatment of patients with RCDI and eliminated antibiotic resistance genes in these patients. FMT resulted in a resolution of symptoms which correlated directly with the elimination of pathogenic microbes and antibiotic resistance genes.
Braden Millan and Karen Madsen
Department of Medicine, Center of Excellence for Gastrointestinal Inflammation and Immunity Research,
University of Alberta, Edmonton, Alberta Canada
Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection.
Millan B, Park H, Hotte N, Mathieu O, Burguiere P, Tompkins TA, Kao D, Madsen KL
Clin Infect Dis. 2016 Mar 29